Abstract

Abstract Anticoagulant therapy is pivotal in managing atrial fibrillation (AF) to prevent stroke and systemic embolism. This article presents a comparative analysis of warfarin and direct oral anticoagulants (DOACs) in optimizing anticoagulant therapy for AF. While warfarin has been the standard therapy for decades, DOACs offer advantages such as predictable anticoagulant effects, fewer drug interactions, and simplified dosing regimens. Clinical trials have shown non-inferiority or superiority of DOACs over warfarin in stroke prevention with a lower risk of intracranial hemorrhage. However, considerations such as cost and patient-specific factors should guide treatment selection. This analysis aims to assist clinicians in making informed decisions to improve outcomes in AF management.